111, Inc. Launches New Video Interview Series on China's Healthcare Landscape
SHANGHAI, Aug. 15, 2019 /PRNewswire/ -- Starting in August 2019, 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, will launch "111 Insight", a video series on the development of the healthcare industry in China.
The series is produced by 111, Inc., and will be hosted by Dr. Gang Yu, Co-Founder and Executive Chairman, and Mr. Junling Liu, Co-Founder, Chairman and CEO. 111 Insight will focus on hot topics in the healthcare industry through interviews with industry experts, investors, and healthcare professionals.
The healthcare industry in China is evolving rapidly and there is increasing global interest in China's health reform and policies. Among the hot topics are how the internet is reshaping China's healthcare industry and pharmaceutical delivery, how new government policies and regulation impact the healthcare industry, how new technologies affect private health insurance, and the opportunities and challenges facing China's aging population, etc.
The first video in series is How the Internet is Changing the Healthcare Industry, hosted by Mr. Junling Liu, Co-Founder, Chairman and CEO of 111, Inc. with guests Ms. Angela Xu, Vice President and CMO of Eli Lilly China, and Dr. Darren Ji, CEO of Elpiscience Biopharma, Ltd.
Video Link:
111 IR website: http://ir.111.com.cn
Tencent video: https://v.qq.com/x/page/t09130n33vi.html
Topics include:
- Quality of medical resources through internet-based healthcare platforms
- Healthcare services - from healthcare delivery to patient-focused models
- 111, Inc. - building a revolutionary healthcare service system
The next installments in the "111 Insight" series are entering production and will delve into the impact of technology on healthcare in China.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading integrated online and offline healthcare platform in China. The Company provides hundreds of millions of consumers with better access to pharmaceutical products and medical services directly through its online retail pharmacy and indirectly through its offline pharmacy network. 111 also offers online medical services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation and electronic prescription services. In addition to providing direct services to consumers through its online retail pharmacy, 111 also enables offline pharmacies to better serve their customers. The Company's online wholesale pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. The Company's New Retail platform, by integrating the front and back ends of the pharmaceutical supply chain, has formed a smart supply chain, which transforms the flow of pharmaceutical products to pharmacies and modernizes how they serve their customers.
For more information on 111, please visit http://ir.111.com.cn/
For more information, please contact:
111, Inc.
Ms. Monica Mu
IR Director
ir@111.com.cn
Christensen
In China
Mr. Christian Arnell
Phone: +86-10-5900-1548
E-mail: carnell@christensenir.com
In U.S.
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: lbergkamp@ChristensenIR.com
SOURCE 111, Inc.
Share this article